SAB Biotherapeutics (SABS) Amortizatization of Intangibles (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Amortizatization of Intangibles came in at $21705.0 in Q1 2026, little changed YoY from $21706.0 in Q1 2025, and down 8.15% on a QoQ basis from $23631.0 in Q4 2025.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Amortizatization of Intangibles data on file, last reported at $21705.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles changed 0.0% year-over-year to $21705.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89336.0 (down 62.43% YoY) and the FY2025 annual result came in at $88631.0, down 62.62% from the prior year.
- Amortizatization of Intangibles retreated to $21705.0 in Q1 2026, from $23631.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $172093.0 in Q4 2024 to a low of $21705.0 in Q1 2026.
- A 5-year average of $37256.3 and a median of $23631.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles jumped 477.9% — and 2025, when it tumbled 86.27%.
- Tracing SABS's Amortizatization of Intangibles over 5 years: stood at $24716.0 in 2022, then climbed by 20.48% to $29779.0 in 2023, then jumped by 477.9% to $172093.0 in 2024, then plunged by 86.27% to $23631.0 in 2025, then slipped by 8.15% to $21705.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $21705.0 (Q1 2026), $23631.0 (Q4 2025), and $22000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | 22,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22,000.00 |
| Mar 31, 2026 | 22,000.00 |
| Dec 31, 2025 | 34,883.00 |
| Sep 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | 19,344.00 |
| Sep 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | 83,994.00 |
| Dec 31, 2023 | 29,779.00 |
| Sep 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 24,716.00 |
| Sep 30, 2022 | 24,717.00 |
| Jun 30, 2022 | 31,809.00 |
| Mar 31, 2022 | 41,207.00 |
| Dec 31, 2021 | 41,206.00 |
| Sep 30, 2021 | 41,259.00 |